Previous 10 | Next 10 |
home / stock / bct:cc / bct:cc news
Prevail Partners, LLC to purchase 463,408 BriaCell common shares at a price of $8.63 for gross proceeds of $4 million, representing a 20% premium to the trailing thirty (30) trading day VWAP. Prevail InfoWorks, Inc. to act as Contract Research Organization (CRO) for BriaCell’...
A significant medical breakthrough is sorely needed in the fight against breast cancer. According to the American Cancer Society, more than 3.1 million women in the United States have a history of invasive breast cancer. And breast cancer deaths are estimated to be more than 43,000 per year ...
15 of 18 patients remain alive of those recruited since the study reopened in 2021. Longer than expected patient survival data highlights tolerability and clinical effectiveness of BriaCell’s combination treatment. The Bria-IMT ™ combination regimen...
SpinCo Assets (SpinCo) includes Bria-TILsRx™, and protein kinase C delta (PKCδ) inhibitors for multiple indications including cancer. SpinCo’s goal is to potentially accelerate the development of its assets, and to create value. PHILADELPHIA and VANCOU...
2023-03-24 09:00:16 ET FN Media Group Presents USA News Group News Commentary Vancouver, BC – March 24, 2023 – USA News Group – Treatments for various forms of breast cancer continue to evolve, with several new breakthroughs being labeled as ...
PHILADELPHIA and VANCOUVER, British Columbia, March 15, 2023 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company specializing in targeted immunotherapies for cancer, has ...
9 of 11 women remain alive from 2021/2022 dosing, highlighting strong survival benefits. Remains well tolerated with no dose limiting toxicities. Primary endpoint in pending pivotal trial will be survival, as agreed by the FDA. 9 additional patients have been s...
PHILADELPHIA and VANCOUVER, British Columbia, Feb. 09, 2023 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX:BCT) (“BriaCell” or the “Company”) , a clinical-stage biotechnology company specializing in targeted immunotherapies for cancer, i...
Positive FDA feedback on our pivotal study for lead clinical candidate Bria-IMT™ in combination with a checkpoint inhibitor could greatly accelerate the path to commercialization. Successful completion of the pivotal study could be followed by a Biologics License Application su...
PHILADELPHIA and VANCOUVER, British Columbia, Jan. 23, 2023 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company specializing in targeted immunotherapies for cancer, annou...
News, Short Squeeze, Breakout and More Instantly...
Briacell Therapeutics Corp. Company Name:
BCT:CC Stock Symbol:
TSXC Market:
Briacell Therapeutics Corp. Website:
A look at the top 10 most actives in Canada Canadian Natural Resources Limited (CNQ) rose 0.2% to $48.92 on volume of 19,781,731 shares iShares S&P/TSX 60 Index ETF (XIU) fell 0.5% to $34.3919 on volume of 13,629,336 shares Constellation Software Inc. Unsecured Subordinated Floating R...
A look at the top 10 most actives in Canada Constellation Software Inc. Unsecured Subordinated Floating Rate Debentures Series 1 (CSU.DB) rose 0.4% to $123 on volume of 12,106,000 shares Royal Bank of Canada (RY) rose 0.4% to $154 on volume of 4,630,267 shares iShares S&P/TSX 60 Index...
Progression free survival (PFS) extended to 9.1 months in ADC resistant patient - quadruple the PFS of patients in similar studies 1, 2, 3 Significant reduction of “Eye-Bulging” metastatic breast cancer tumor was previously rep...